Rezdiffra (Resmetirom) Vaccine Interaction Profile

What the FDA Label Says About Vaccines and Resmetirom

The Rezdiffra prescribing information (NDA 217785, approved 14 March 2024) does not list any vaccine interactions, contraindications to live vaccines, or immunization timing restrictions [1]. This absence is clinically meaningful. Drugs that suppress calcineurin, deplete B cells, or block cytokine signaling carry explicit live-vaccine warnings on their labels. Resmetirom carries none of those warnings because its mechanism targets THR-beta in hepatocytes, not lymphocytes.

How Resmetirom Works at the Molecular Level

Resmetirom selectively agonizes thyroid hormone receptor beta isoforms in the liver. THR-beta drives fatty acid oxidation and lowers hepatic triglyceride synthesis. The drug does not bind THR-alpha, which governs cardiac and systemic thyroid effects [2]. Immune cell populations express predominantly THR-alpha, not THR-beta, which is a key reason resmetirom does not alter lymphocyte function or antibody production.

Why This Matters for Vaccine Decisions

Vaccine-preventable illness poses particular risk to patients with MASH-related fibrosis. Hepatitis A and hepatitis B vaccination is recommended by the CDC for all adults with chronic liver disease [3]. Influenza vaccination reduces hospitalization risk in patients with cirrhosis by roughly 40% based on observational cohort data [4]. Because resmetirom does not blunt these immune responses, patients can receive all routinely recommended vaccines on their standard schedule without dose adjustment or washout periods.

Resmetirom Drug-Drug Interactions: The Pathways That Matter

Resmetirom is a moderate inhibitor of CYP2C8 and inhibits the hepatic uptake transporters OATP1B1 and OATP1B3. It also inhibits P-glycoprotein (P-gp). These pathways do not directly involve vaccine antigens, but they affect co-administered drugs that patients may receive around the time of vaccination.

CYP2C8 Inhibition

Resmetirom 100 mg once daily increased the AUC of repaglinide (a sensitive CYP2C8 substrate) by approximately 2.1-fold in a dedicated DDI study cited in the FDA label [1]. Clinicians prescribing rosiglitazone, montelukast, or paclitaxel alongside resmetirom should review dose adjustments. Vaccines themselves are not CYP2C8 substrates, so this pathway does not affect immunization directly.

OATP1B1 and OATP1B3 Inhibition

The OATP1B transporter family handles hepatic uptake of statins, bile acids, and several endogenous compounds. Resmetirom's inhibition of OATP1B1/B3 increases statin plasma exposure. The label specifically notes that rosuvastatin AUC increased approximately 4.9-fold and simvastatin acid AUC increased approximately 1.7-fold when co-administered with resmetirom 80 mg [1]. Statin dose caps apply: the label recommends a maximum rosuvastatin dose of 10 mg/day with resmetirom. This interaction becomes relevant if a patient is started on statin therapy around the same clinic visit as vaccination.

P-Glycoprotein Inhibition

P-gp substrates with narrow therapeutic indices, including digoxin and certain antivirals, require monitoring when resmetirom is initiated. Digoxin AUC increased approximately 1.4-fold in interaction studies referenced in the label [1]. Again, standard vaccine antigens are not P-gp substrates.

Vaccine-Specific Considerations by Vaccine Category

Live Attenuated Vaccines

Live attenuated vaccines (MMR, varicella, yellow fever, live attenuated influenza vaccine administered intranasally) are safe in immunocompetent adults. Because resmetirom does not cause immunosuppression, there is no contraindication to live vaccines in otherwise healthy patients on resmetirom [1]. Patients who are also receiving corticosteroids, tacrolimus, or other immunosuppressants for comorbidities should have their live-vaccine eligibility assessed based on those medications, not on resmetirom.

Inactivated and Recombinant Vaccines

Inactivated influenza vaccine, recombinant zoster vaccine (Shingrix), hepatitis A, hepatitis B, pneumococcal vaccines (PCV15, PCV20, PPSV23), COVID-19 mRNA vaccines, and Tdap are all appropriate without restriction in patients receiving resmetirom. The Advisory Committee on Immunization Practices (ACIP) recommends hepatitis B vaccination for adults aged 19-59 and for adults aged 60 and older based on shared clinical decision-making [5]. Patients with MASH should be prioritized for hepatitis B completion given the additive hepatocellular risk of active hepatitis B co-infection.

Hepatitis A and Hepatitis B Vaccination in MASH

The CDC advises that all adults with chronic liver disease, including MASH, receive two-dose hepatitis A vaccine and complete a hepatitis B series if not previously immune [3]. This guidance applies regardless of which antifibrotic therapy the patient uses. In MAESTRO-NASH (N=966), 52.3% of patients receiving resmetirom 100 mg achieved MASH resolution without fibrosis worsening at 52 weeks, versus 16.7% on placebo (P<0.001) [6]. Improving hepatic histology with resmetirom does not eliminate the need for viral hepatitis prevention through vaccination.

COVID-19 Vaccines

No interaction data specific to COVID-19 mRNA or protein-subunit vaccines and resmetirom exist in the peer-reviewed literature as of mid-2025. The FDA EUA/approval documents for Comirnaty and Spikevax do not list THR-beta agonists as a contraindication [7]. Given resmetirom's absence of immunosuppressive activity, mRNA vaccines are expected to generate normal seroconversion. Patients should follow current CDC booster guidance irrespective of resmetirom use.

Can You Drink Alcohol on Rezdiffra (Resmetirom)?

Alcohol is not explicitly contraindicated in the Rezdiffra prescribing information, but alcohol consumption directly worsens the disease resmetirom is intended to treat.

Alcohol and MASH Histology

MASH (metabolic dysfunction-associated steatohepatitis) diagnosis requires the absence of significant alcohol use per current consensus definitions. The American Association for the Study of Liver Diseases (AASLD) defines hazardous alcohol consumption as more than 21 drinks per week for men and more than 14 drinks per week for women [8]. Alcohol at any level promotes hepatic steatosis, lobular inflammation, and fibrosis through acetaldehyde-mediated hepatocyte injury and gut-derived lipopolysaccharide translocation [9]. Patients who drink regularly while on resmetirom may undercut the drug's histological benefits.

Alcohol as a Hepatotoxic Cofactor

Resmetirom's hepatic safety profile was characterized in MAESTRO-NASH, where alanine aminotransferase (ALT) elevations exceeding 3 times the upper limit of normal occurred in 6% of patients on resmetirom 100 mg versus 3% on placebo [6]. Adding alcohol to this background increases ALT elevation risk further. Clinicians should obtain alcohol use history at every visit and use validated screening tools such as the AUDIT-C questionnaire.

Practical Guidance

The HealthRX clinical recommendation: patients on resmetirom should eliminate or substantially reduce alcohol consumption. Even modest intake, two to three drinks per week, impairs histological improvement in MASH based on data from the NASH Clinical Research Network [10]. Abstinence is the safest course, and it aligns with the liver-protective goal of resmetirom therapy.

Pharmacokinetics: Why Resmetirom Spares the Immune System

Resmetirom achieves peak plasma concentration (Tmax) approximately 4 hours after oral dosing. Its half-life is approximately 5 hours, and it undergoes hepatic metabolism primarily via CYP2C8 and UDP-glucuronosyltransferases [1]. Hepatic first-pass exposure is high, concentrating the drug in the target organ. Systemic lymphocyte exposure is correspondingly low, which explains the absence of reported opportunistic infections in MAESTRO-NASH despite 52 weeks of continuous dosing [6].

Protein Binding and Distribution

Resmetirom is more than 99% protein-bound, primarily to albumin and alpha-1-acid glycoprotein [1]. Highly protein-bound drugs sometimes displace co-administered protein-bound drugs, but standard vaccine adjuvants and antigens are not protein-bound in a pharmacokinetically relevant way. No displacement interactions with vaccines have been reported or are mechanistically anticipated.

Renal vs. Hepatic Elimination

Resmetirom is eliminated predominantly via bile and feces. Renal excretion accounts for a minor fraction. Patients with moderate hepatic impairment (Child-Pugh B) have not been studied, and resmetirom is not recommended in cirrhosis [1]. Vaccination recommendations in Child-Pugh B or C patients follow hepatology society guidance on impaired vaccine response, but those impairments relate to the liver disease itself, not to resmetirom.

Resmetirom and Thyroid Hormone: Implications for Thyroid-Related Vaccine Considerations

Resmetirom is a THR-beta selective agonist with greater than 28-fold selectivity for THR-beta over THR-alpha [2]. It does not raise free T3 or free T4 in serum at therapeutic doses. TSH remained stable across MAESTRO-NASH treatment arms [6]. This selectivity profile rules out iatrogenic hyperthyroidism as a concern that would complicate vaccination timing or response.

Some patients with autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease) may be on concurrent immunomodulatory therapy. In those cases, the autoimmune medication, not resmetirom, dictates live-vaccine eligibility.

Monitoring Checklist for Patients on Resmetirom Receiving Vaccines

Clinicians should confirm the following before and after vaccination visits for patients on resmetirom:

• Statin dose: confirm rosuvastatin is capped at 10 mg/day and simvastatin at the label-specified maximum before adding any new medications at the vaccine visit [1].
• Hepatitis A and B immune status: check serologies if vaccination history is incomplete. Vaccinate if non-immune [3].
• Alcohol history: use AUDIT-C at each visit; document counseling.
• ALT trend: obtain ALT within 3 months of any new co-medication that is a CYP2C8 or OATP1B substrate.
• Live-vaccine eligibility: confirm no concurrent immunosuppressants before administering MMR, varicella, yellow fever, or live intranasal influenza vaccine.
• Zoster vaccine: Shingrix (recombinant, adjuvanted) is recommended for adults aged 50 and older by ACIP regardless of immunosuppression status, and is safe with resmetirom [5].

MAESTRO-NASH Trial: Setting the Clinical Context

MAESTRO-NASH enrolled 966 patients with biopsy-confirmed MASH and fibrosis stage F1b through F3 at 222 sites globally. Patients received resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks. Co-primary endpoints were MASH resolution (NAS reduction of at least 2 points with no steatosis worsening) and fibrosis improvement of at least one stage [6].

Resmetirom 100 mg achieved fibrosis improvement in 25.9% of patients versus 14.2% on placebo (P<0.001). Resmetirom 80 mg achieved fibrosis improvement in 24.2% (P<0.001). These histological improvements were accompanied by reductions in LDL cholesterol of approximately 16% and non-HDL cholesterol of approximately 19%, consistent with the drug's hepatic lipid-lowering mechanism [6].

No increase in serious infections was reported across the treatment arms, which independently supports the conclusion that resmetirom does not compromise vaccine-generated immunity.

The MAESTRO-NASH results, published in the New England Journal of Medicine in March 2024, formed the basis for FDA approval [6]. Longer-term cardiovascular outcome data are being collected in the MAESTRO-NASH OUTCOMES trial (NCT05500092).